620 related articles for article (PubMed ID: 15875098)
1. [Interventional treatment in hypertrophic cardiomyopathy].
Gietzen FH; Schümmelfeder J; Neuser H; Brunn J; Schumacher B; Kerber S
Herz; 2005 Mar; 30(2):102-10. PubMed ID: 15875098
[TBL] [Abstract][Full Text] [Related]
2. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
Lawrenz T; Obergassel L; Lieder F; Leuner C; Strunk-Mueller C; Meyer Zu Vilsendorf D; Beer G; Kuhn H
Pacing Clin Electrophysiol; 2005 Apr; 28(4):295-300. PubMed ID: 15826262
[TBL] [Abstract][Full Text] [Related]
3. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?
Wichter T; Paul TM; Eckardt L; Gerdes P; Kirchhof P; Böcker D; Breithardt G
Herz; 2005 Mar; 30(2):91-101. PubMed ID: 15875097
[TBL] [Abstract][Full Text] [Related]
4. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
5. [Therapy and risk-stratification in hypertrophic cardiomyopathy--a current survey].
Reith S; Klues HG
Z Kardiol; 2003 Apr; 92(4):283-93. PubMed ID: 12707787
[TBL] [Abstract][Full Text] [Related]
6. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
[TBL] [Abstract][Full Text] [Related]
7. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
[TBL] [Abstract][Full Text] [Related]
8. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
[TBL] [Abstract][Full Text] [Related]
9. New trends in treatment of hypertrophic cardiomyopathy.
Hagège AA; Desnos M
Arch Cardiovasc Dis; 2009 May; 102(5):441-7. PubMed ID: 19520330
[TBL] [Abstract][Full Text] [Related]
10. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
McLeod CJ; Ommen SR; Ackerman MJ; Weivoda PL; Shen WK; Dearani JA; Schaff HV; Tajik AJ; Gersh BJ
Eur Heart J; 2007 Nov; 28(21):2583-8. PubMed ID: 17483110
[TBL] [Abstract][Full Text] [Related]
11. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P
J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1118-26. PubMed ID: 18384577
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM].
Maron BJ; Spirito P
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):297-302. PubMed ID: 19791462
[TBL] [Abstract][Full Text] [Related]
14. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.
Limongelli G; Elliott PM; Pacileo G; Sarubbi B; Thaman R; Calabrò P; Vergara P; Iacomino M; Russo MG; Calabrò R
J Cardiovasc Med (Hagerstown); 2006 Sep; 7(9):711-3. PubMed ID: 16932087
[TBL] [Abstract][Full Text] [Related]
16. Management of hypertrophic cardiomyopathy in children.
Seggewiss H; Rigopoulos A
Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
[TBL] [Abstract][Full Text] [Related]
18. Sudden death and hypertrophic cardiomyopathy: a review.
Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D
Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263
[TBL] [Abstract][Full Text] [Related]
19. [Risk stratification for sudden death in hypertrophic cardiomyopathy].
Spirito P; Maron BJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):294-7. PubMed ID: 19791461
[TBL] [Abstract][Full Text] [Related]
20. Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy.
Cotiga D; Ehlert F; Sherrid M
Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():55-60. PubMed ID: 17162272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
